KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Clinical trial NCT07252739 · RECRUITING
Trial details
- NCT number
- NCT07252739
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-19
- Primary completion
- 2033-01-14
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.